Date: 2015-05-29
Type of information: Results
phase: preclinical
Announcement: results
Company: Addex Therapeutics (Switzerland)
Product: dipraglurant (ADX48621)
Action
mechanism: mGluR5 negative allosteric modulator. Dipraglurant is an oral, small molecule allosteric modulator that inhibits selectively the metabotropic glutamate receptor 5 (mGlu5), a Class C G-Protein Coupled Receptor (GPCR), with potential to be used in combination with levodopa or dopamine agonists or as a standalone treatment for Parkinson\'s disease levodopa-induced dyskinesia (PD-LID), motor and non-motor symptoms of Parkinson\'s disease and other movement disorders.
Disease: dystonia
Therapeutic area: Neuromuscular diseases - Rare diseases - CNS diseases - Neurological diseases
Country:
Trial details:
Latest
news: * On May 29, 2015, Addex Therapeutics announced that scientists in the group of Professor Antonio Pisani, University of Rome Tor Vergata will present the progress made in understanding the role of the mGlu5 receptor on corticostriatal synaptic plasticity in a DYT1 knock-in mouse model of DYT1 dystonia and will report the effect of chronic treatment with dipraglurant (ADX48621), a novel small molecule inhibitor of the metabotropic glutamate receptor 5, in rescuing the synaptic plasticity deficits in the DYT1 knock-in mouse model. Chronic treatment with dipraglurant (50 mg/kg i.p. for 8 days) partially restored long-term depression and synaptic de-potentiation in a validated model for primary generalized torsion dystonia 1 (DYT1), a common and severe genetic form of dystonia, caused by a mutation in the TOR1A gene encoding the torsin A protein. Addex recently reported entering a collaboration with prof. Pisani to evaluate the effect of chronic treatment with dipraglurant (ADX48621), on rescuing the synaptic plasticity deficits, in several models of genetic forms of dystonia, including the DYT1 knock-in mouse model.
